



<p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>LIST OF PRIOR ART CITED BY APPLICANT</p>	<p>ATTY. DOCKET NO. T7770.CON3</p>	<p>SERIAL NO. 10/731,041</p>
	<p>APPLICANT Steven W. Sanders, et al.</p>	
	<p>FILING DATE Dec. 8, 2003</p>	<p>GROUP 1613</p>

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JD</i>	A1	4,652,441	3/24/87	Okada, et al.			
	A2	4,959,217	9/25/90	Sanders, et al.			
	A3	5,028,430	7/2/91	Sanders, et al.			
	A4	5,152,997	10/6/92	Ebert, et al.			
	A5	5,164,190	11/17/92	Patel, et al.			
	A6	5,212,199	5/18/93	Heiber, et al.			
	A7	5,227,169	7/13/93	Heiber, et al.			
	A8	5,411,740	5/2/95	Lee, et al.			
	A9	5,500,222	3/19/96	Lee, et al.			
	A10	5,516,808	5/14/96	Sawaya			
	A11	5,532,278	7/2/96	Aberg, et al.			
	A12	5,575,987	11/19/96	Kamei, et al.			
	A13	5,582,838	12/10/96	Rork, et al.			
	A14	5,601,839	2/11/97	Quan, et al.			
	A15	5,614,211	3/25/97	Gale, et al.			
	A16	5,626,866	5/6/97	Ebert, et al.			
	A17	5,641,504	6/24/97	Lee, et al.			
	A18	5,643,584	7/1/97	Farnig, et al.			
	A19	5,674,895	10/7/97	Guiltard, et al.			
	A20	5,677,346	10/14/97	Aberg, et al.			
	A21	5,721,275	2/24/98	Bazzano			
	A22	5,736,577	4/7/98	Aberg, et al.			
	A23	5,747,065	5/5/98	Lee, et al.			
	A24	5,759,583	6/2/98	Iwamoto, et al.			
	A25	5,762,953	6/9/98	Venkateshwaran			
	A26	5,783,208	7/21/98	Venkateshwaran, et al.			
<i>JD</i>	A27	5,840,754	11/24/98	Guiltard, et al.			
<i>JD</i>	A28	5,862,555	1/26/99	Furuhashi			

PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. T7770.CON3	SERIAL NO. 10/731,041
		APPLICANT Steven W. Sanders, et al.	
		FILING DATE December 8, 2003	GROUP 1613

LIST OF PRIOR ART CITED BY APPLICANT

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>P</i>	A29	5,891,462	4/6/99	Carrara			
	A30	5,891,920	4/6/99	Hirano, et al.			
	A31	5,900,250	5/4/99	Lee, et al.			
	A32	5,912,268	6/15/99	Guittard, et al.			
	A33	5,922,342	7/13/99	Shah, et al.			
	A34	5,939,094	8/17/99	Durif, et al.			
	A35	5,948,433	9/7/99	Burton, et al.			
	A36	5,972,369	10/26/99	Roorda, et al.			
	A37	5,985,305	11/16/99	Perry, et al.			
	A38	5,985,317	11/16/99	Venkateshwaran, et al.			
	A39	6,096,339	8/1/2000	Ayer, et al.			
	A40	6,187,323	2/13/01	Alache, et al.			
	A41	6,203,817	3/20/01	Cormier, et al.			
	A42	6,258,830	7/10/01	Charu			
	A43	6,319,913	11/20/01	Mak, et al.			
	A44	Pub. No. 0147236A1	10/10/02	Sanders, et al.			
	A45	Pub. No. 0031787A1	10/18/01	Hsu, et al.			
<i>P</i>	A46	Pub. No. 0161044A1	10/31/02	Sherratt, et al.			

FOREIGN PATENT DOCUMENTS


EXAMINER INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>P</i>	A47	WO 99/48494	9/30/99	Europe			
	A48	WO 92/10231	6/25/92	Europe			
	A49	WO 92/20377	11/26/92	Europe			
	A50	WO 93/23025	11/25/93	Europe			
<i>P</i>	A51	WO 95/09007	4/6/95	Europe			

PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF PRIOR ART CITED BY APPLICANT	ATTY. DOCKET NO. T7770.CON3	SERIAL NO. 10/731,041
	APPLICANT Steven W. Sanders, et al.	
	FILING DATE December 8, 2003	GROUP 1613

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>AS</i>	AS2	WO 99/48493	9/30/99	Europe	<i>AS</i>	<i>AS</i>	

OTHER PRIOR ART (Including Author, Title, Pertinent Pages, Etc.)

<i>P</i>	AS3	L. NORONHA-BLOB and J. F. KACHUR, <i>Enantiomers of Oxybutynin: In Vitro Pharmacological Characterization at M₁, M₂ and M₃ Muscarinic Receptors and in Vivo Effects on Urinary Bladder Contraction, Mydriasis and Salivary Secretion in Guinea Pigs</i> , Journal of Pharmacology and Experimental Therapeutics, 256: 562-567, (1990).
<i>EP</i>	AS4	ERNEST W. MERRITT and EUGENE R. COOPER, <i>Diffusion Apparatus for Skin Penetration</i> , Journal of Controlled Release, 1: 161-162, (1984).
<i>AS</i>	AS5	JAMES F. KACHUR, JAN S. PETERSON, J. PAUL CARTER, W. JANUSZ RZESZOTARSKI, ROBERT C. HANSON and LALITA NORONHA-BLOB, <i>R and S Enantiomers of Oxybutynin: Pharmacological Effects in Guinea Pig Bladder and Intestine</i> , The Journal of Pharmacology and Experimental Therapeutics, 247: 3, 867-872, (1988).
EXAMINER <i>Jis Ghalc</i>		DATE CONSIDERED <i>04/07/05</i>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.</p>		

	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. T7770.CON3	SERIAL NO. 10/731,041
	LIST OF PRIOR ART CITED BY APPLICANT		APPLICANT Watson Pharmaceuticals, Inc.	
			FILING DATE 12/08/2003	GROUP 1613

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JP</i>	A1	6,039,967	21-Mar-00	Ottoboni et al.			
<i>JP</i>	A2	6,562,368	13-May-03	Hsu et al.			
	A3						
	A4						
	A5						
	A6						
	A7						
	A8						
	A9						
	A10						
	A11						
	A12						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	A13						
	A14						
	A15						
	A16						
	A17						

OTHER PRIOR ART (Including Author, Title, Pertinent Pages, Etc.)

	A18	
	A19	
	A20	

EXAMINER <i>Jim Ghal</i>	DATE CONSIDERED <i>10/7/05</i>
-----------------------------	-----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.